X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com//news-release/2024/03/11/2843634/0/en/Replay-s-cell-therapy-product-company-Syena-announces-first-patient-dosed-in-Phase-1-2-study-of-TCR-NK-cell-therapy-for-multiple-myeloma.html
https://www.globenewswire.com//news-release/2023/12/18/2797661/0/en/Replay-s-oncology-focused-product-company-Syena-and-Miltenyi-Biotec-enter-into-exclusive-licensing-and-GMP-manufacturing-agreement-for-PRAME-TCR-NK-cell-therapy-based-on-CliniMACS-.html
https://www.globenewswire.com//news-release/2023/12/18/2797689/0/en/Replay-and-its-engineered-NK-cell-therapy-company-Syena-announce-exclusive-licensing-agreement-with-National-Institutes-of-Health-for-TCRs-targeting-cancer-neoantigens.html
https://www.globenewswire.com//news-release/2023/09/21/2747189/0/en/Replay-announces-partnership-between-product-company-Syena-and-JURA-Bio-to-advance-T-cell-receptor-NK-therapies-in-cancer.html
https://www.globenewswire.com/news-release/2023/07/24/2709407/0/en/Replay-and-MD-Anderson-announce-FDA-clearance-of-IND-application-for-first-in-class-T-Cell-Receptor-Natural-Killer-TCR-NK-cell-therapy-for-multiple-myeloma.html
https://www.globenewswire.com/news-release/2023/06/20/2690890/0/en/Replay-and-MD-Anderson-announce-FDA-clearance-of-IND-application-for-first-in-class-T-Cell-Receptor-Natural-Killer-TCR-NK-cell-therapy-for-sarcoma.html
https://www.globenewswire.com/news-release/2023/05/25/2675965/0/en/Cristian-Massacesi-M-D-Appointed-to-Replay-Board-of-Directors.html
https://www.globenewswire.com/news-release/2023/05/18/2671841/0/en/Replay-Appoints-Arun-Balakumaran-M-D-Ph-D-as-Chief-Medical-Officer.html
https://www.globenewswire.com/news-release/2023/02/14/2607462/0/en/KKR-backed-Replay-and-MD-Anderson-form-new-product-company-Syena-to-pioneer-first-in-class-TCR-NK-cell-therapy.html
https://www.fiercebiotech.com/biotech/replay-rolls-again-creating-tcr-nk-cell-therapy-startup-md-anderson-close-clinic
Market Place
Share 
